Ambient Biosciences

Executive Summary

Ambient Biosciences, founded in 2021 and based in Cambridge, Massachusetts, is developing a novel platform to stabilize temperature-sensitive biomolecules—such as reagents, enzymes, antibodies, and other biological materials—at ambient temperatures. The technology aims to eliminate the need for cold chain logistics and lyophilization, which are costly and logistically challenging, especially in resource-limited settings. By enabling room-temperature storage and transport, Ambient’s solution promises to simplify storage, extend shelf life, and reduce costs for research, diagnostics, and biotherapeutic development. The company addresses a critical unmet need in the life sciences industry, where cold chain dependency poses significant barriers to global distribution and access. Although still in early stages with no disclosed funding or revenue, Ambient’s platform has the potential to disrupt supply chains and accelerate innovation across multiple sectors.

Upcoming Catalysts (preview)

• TBDProof-of-Concept Study Publication or Presentation60% success
• TBDStrategic Partnership with Diagnostic or Pharma Company50% success
• TBDSeries A Funding Round Announcement70% success